ArticleThe Pan African medical journal2025
Concordance between initial GeneXpert MTB/RIF results and follow-up diagnostic testing in patients treated for multidrug-resistant tuberculosis in Lusaka, Zambia.
Article in The Pan African medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: diagnosis of multi-drug-resistant (MDR) tuberculosis (TB) has been revolutionized by the introduction of the GeneXpert MTB/RIF test, which is much faster and easier to use than traditional methods. Concerns have been raised about false positive results for rifampicin susceptibility, especially in cases of samples with low bacillary loads and settings with a low burden of MDR-TB. The objective of this study was to assess the concordance between initial GeneXpert MTB/RIF results and subsequent diagnostic testing for rifampicin susceptibility in patients with suspected MDR-TB in Lusaka, Zambia. Methods: this was a retrospective cohort study of patients who started MDR-TB treatment in Lusaka province, Zambia, from 2019 to 2021. Initial GeneXpert MTB/RIF bacillary load and rifampicin susceptibility, as well as results for any confirmatory testing on rifampicin resistance (including repeat GeneXpert MTB/RIF, phenotypic drug susceptibility testing, and line probe assay results) and patient outcomes were collected from patient files. Results: the study included 342 patients. Initiation of MDR-TB treatment was based on rifampicin resistance detected by GeneXpert MTB/RIF in all patients. Twenty-nine percent of patients had a very low bacillary load in the initial sample. Additional diagnostics for rifampicin resistance were available in 56% of patients, and revealed rifampicin susceptibility in 28% of tested patients. Rifampicin-susceptible TB was found more often if the bacillary load in the initial sample was very low (78% versus 18%; p=0.0001). Conclusion: false positive results for rifampicin susceptibility on GeneXpert MTB/RIF appear to be common in Lusaka, Zambia, especially in patients with very low bacillary loads on the initial test. Repeat testing to confirm MDR-TB prior to initiation of treatment can be considered in this group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.